Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC)

被引：0
|
作者：
Taylor, Melissa
Reddy, Shilpa
Kumar, Prashanth Ashok
Hariri, Dana
Sokol, Ethan
Sivakumar, Smruthy
Quintanilha, Julia
Pavlick, Dean
Levy, Mia Alyce
Ross, Jeffrey S.
Lustberg, Maryam B.
机构：
[1] Yale New Haven Hosp, New Haven, CT USA
[2] Upstate Univ Hosp, Syracuse, NY USA
[3] SUNY Upstate Univ Hosp, Syracuse, NY USA
[4] Fdn Med Inc, Cambridge, MA USA
[5] Fdn Med Inc, Boston, MA USA
[6] Fdn Med, Cambridge, MA USA
[7] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1092
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
    Sanomachi, Tomomi
    Okuma, Hitomi Sumiyoshi
    Kitadai, Rui
    Kawachi, Asuka
    Yazaki, Shu
    Tokura, Momoko
    Arakaki, Motoko
    Saito, Ayumi
    Kita, Shosuke
    Yamamoto, Kasumi
    Maejima, Aiko
    Kojima, Yuki
    Nishikawa, Tadaaki
    Sudo, Kazuki
    Shimoi, Tatsunori
    Noguchi, Emi
    Fujiwara, Yasuhiro
    Sugino, Hirokazu
    Shiino, Sho
    Suto, Akihiko
    Yoshida, Masayuki
    Yonemori, Kan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [32] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
    Fehm, T.
    Lane, N.
    Solomayer, E.
    Wallwiener, D.
    Uhr, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
  • [33] Deciphering the Clinicopathological, Immunological and Molecular Profile of HER2 Low Breast Cancer within Luminal and Triple-negative Breast Cancer
    Atallah, N.
    Rakha, E.
    JOURNAL OF PATHOLOGY, 2023, 261 (SUPPL1): : S18 - S18
  • [34] Assessment of HER2 status in breast cancer
    Penault-Llorca, F
    Cayre, A
    BULLETIN DU CANCER, 2004, 91 : S211 - S215
  • [35] Neoadjuvant therapy in patients with triple negative and HER2 positive early breast cancer
    Harbeck, N.
    BREAST, 2017, 32 : S18 - S18
  • [36] HER2 status in bilateral breast cancer
    Crowe, Joseph P.
    Patrick, Rebecca J.
    Rybicki, Lisa A.
    Budd, G. Thomas
    Escobar, Pedro F.
    Tubbs, Raymond R.
    Hicks, David G.
    INTERNATIONAL JOURNAL OF FERTILITY AND WOMENS MEDICINE, 2006, 51 (05) : 219 - 223
  • [37] Impact of neoadjuvant HER2-directed therapy on HER2 status in breast cancer
    Manguso, Nicholas
    Johnson, Jeffrey
    Basho, Reva Kakkar
    McArthur, Heather L.
    Tanaka, Hisashi
    Giuliano, Armando E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Prognostic factors in nonmetastatic HER2 'low' & HER2 'negative' breast cancer: Single institute experience
    Turkel, A.
    Dogan, M.
    Sertesen, E.
    Karacin, C.
    Irkkan, S. C.
    Ates, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S299 - S300
  • [39] BASELINE PRESENTATION OF TRIPLE NEGATIVE BREAST CANCER (TNBC) AND HER2+/NEU BREAST CANCER AT A CENTRE IN SOUTH INDIA
    Narang, N. Raizada
    B, M. K.
    Thomas, T.
    Bs, A. Kumar
    ANNALS OF ONCOLOGY, 2010, 21 : 116 - 116
  • [40] Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
    Jie Li
    Maoguang Ma
    Xuesong Yang
    Maolei Zhang
    Jingyan Luo
    Huangkai Zhou
    Nunu Huang
    Feizhe Xiao
    Bingquan Lai
    Weiming Lv
    Nu Zhang
    Molecular Cancer, 19
12345